Literature DB >> 26458766

SMFM Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening.

.   

Abstract

The purpose of this statement is to clarify that the Society for Maternal-Fetal Medicine (SMFM) does not recommend that cell-free DNA aneuploidy screening be offered to all pregnant women, nor does it suggest a requirement for insurance coverage for cell-free DNA screening in women at low risk of aneuploidy. However, SMFM believes, due to the ethics of patient autonomy, that the option should be available to women who request additional testing beyond what is currently recommended by professional societies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell-free DNA aneuploidy screening; diagnostic testing; genetic testing; prenatal aneuploidy screening

Mesh：

Substances：

Year:  2015        PMID： 26458766     DOI： 10.1016/j.ajog.2015.09.077

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


  8 in total

1.  Quantitative MRI Analyses of Regional Brain Growth in Living Fetuses with Down Syndrome.

Authors:  Tomo Tarui; Kiho Im; Neel Madan; Rajeevi Madankumar; Brian G Skotko; Allie Schwartz; Christianne Sharr; Steven J Ralston; Rie Kitano; Shizuko Akiyama; Hyuk Jin Yun; Ellen Grant; Diana W Bianchi
Journal:  Cereb Cortex       Date:  2020-01-10       Impact factor: 5.357

2.  Primary Cesarean Delivery Patterns among Women with Physical, Sensory, or Intellectual Disabilities.

Authors:  Blair G Darney; Frances M Biel; Brian P Quigley; Aaron B Caughey; Willi Horner-Johnson
Journal:  Womens Health Issues       Date:  2017-01-18

Review 3.  Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening.

Authors:  Kathryn J Gray; Louise E Wilkins-Haug
Journal:  Pediatr Radiol       Date:  2018-03-17

4.  Informed decision-making about prenatal cfDNA screening: An assessment of written materials.

Authors:  Marsha Michie; Stephanie A Kraft; Mollie A Minear; Roberta R Ryan; Megan A Allyse
Journal:  Ethics Med Public Health       Date:  2016-09-13

5.  Sociodemographic and attitudinal predictors of simultaneous and redundant multiple marker and cell-free DNA screening among women aged ⩾35 years.

Authors:  A K Lewkowitz; A J Kaimal; K Thao; A O'Leary; O Nseyo; M Kuppermann
Journal:  J Perinatol       Date:  2017-05-11       Impact factor: 2.521

6.  Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening.

Authors:  Andrew P Dervan; Patricia A Deverka; Julia R Trosman; Christine B Weldon; Michael P Douglas; Kathryn A Phillips
Journal:  Genet Med       Date:  2016-09-22       Impact factor: 8.822

7.  Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics.

Authors:  Anthony R Gregg; Brian G Skotko; Judith L Benkendorf; Kristin G Monaghan; Komal Bajaj; Robert G Best; Susan Klugman; Michael S Watson
Journal:  Genet Med       Date:  2016-07-28       Impact factor: 8.822

8.  Abortion for Fetal Genetic Abnormalities: Type of Abnormality and Gestational Age at Diagnosis.

Authors:  Tracy B Grossman; Stephen T Chasen
Journal:  AJP Rep       Date:  2020-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.